{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-22-000034","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2022-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.755662+00:00","generated_at":"2026-06-27T07:13:06.589645+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artivion Q4 revenue record $79.4M (+16.9%), net loss widens to $20.1M; guides 2022 rev $319-325M","bullets":["Q4 revenue $79.4M, up 16.9% GAAP; net loss ($20.1M) vs ($3.5M) in prior year.","Non-GAAP Q4 net loss ($141K) vs income $7.9M; full year non-GAAP net income $4.9M.","Full year revenue $298.8M (+18%); net loss ($14.8M) narrowed from ($16.7M) in 2020.","2022 outlook: constant currency revenue growth 9-11%; GAAP revenue $319-325M with $6M FX headwind.","FDA approved AMDS trial start; PMA filed for PerClot US approval; PROACT trials progressing."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-22-000034","json":"https://secwatch.observer/filing/0000784199-22-000034.json","markdown":"https://secwatch.observer/filing/0000784199-22-000034.md","text":"https://secwatch.observer/filing/0000784199-22-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419922000034/0000784199-22-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419922000034/aort-20220217x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:13:06.589645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}